SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria
JAMA · 20.01.2026 · 335 (3) · 233
DOI: 10.1001/jama.2025.20834 ↗Kurz gefasst
Metaanalyse in der Zeitschrift JAMA, erschienen am 20.01.2026. Verfasst von Brendon L Neuen und 28 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Albuminuria, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Kidney Failure, Chronic. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce chronic kidney disease (CKD) progression in individuals with type 2 diabetes, CKD, or heart failure. However, their effects in those with stage 4 CKD or little to no albuminuria remain uncertain.
Objective
To assess whether estimated glomerular filtration rate (eGFR) or degree of albuminuria, measured by urinary albumin to creatinine ratio (UACR), modifies the effects of SGLT2 inhibitors on kidney outcomes. Data Sources SGLT2 inhibitor trials participating in the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (SMART-C). Study Selection Randomized, double-blind, placebo-controlled trials within SMART-C evaluating an SGLT2 inhibitor with label indications for reducing CKD progression including at least 500 participants in each group with at least 6 months of follow-up. Data Extraction and Synthesis Treatment effects in individual trials were pooled using inverse variance–weighted meta-analysis. Main Outcomes and Measures CKD progression, defined as kidney failure, at least 50% reduction in eGFR, or death due to kidney failure. Other outcomes included annual rate of eGFR decline and kidney failure.
Results
Among 70 361 participants (mean [SD] age, 64.8 [8.7] years; 24 595 [35.0%] females) in 10 randomized trials, 2314 (3.3%) experienced CKD progression and 988 (1.4%) reached kidney failure. SGLT2 inhibitors reduced the risk of CKD progression (25.4 vs 40.3 events per 1000 patient-years; hazard ratio [HR], 0.62 [95% CI, 0.57-0.68]), irrespective of baseline eGFR (HR of 0.61 [95% CI, 0.52-0.71] for eGFR ≥60 mL/min/1.73 m 2 ; 0.57 [95% CI, 0.47-0.70] for eGFR of 45 to <60 mL/min/1.73 m 2 ; 0.64 [95% CI, 0.54-0.75] for eGFR of 30 to <45 mL/min/1.73 m 2 ; and 0.71 [95% CI, 0.60-0.83] for eGFR <30 mL/min/1.73 m 2 ; P for trend = .16) and baseline albuminuria (HR of 0.58 [95% CI, 0.44-0.76] for albuminuria ≤30 mg/g; 0.74 [95% CI, 0.57-0.96] for >30-300 mg/g; and 0.57 [95% CI, 0.52-0.64] for more than 300 mg/g; P for trend = .49). Although the magnitude of protection varied, SGLT2 inhibitors reduced the annual rate of eGFR decline across all eGFR and UACR subgroups, including when participants with and without diabetes were analyzed separately. SGLT2 inhibitors also reduced the risk of kidney failure alone (HR, 0.66 [95% CI, 0.58-0.75]). Conclusions and Relevance In this meta-analysis, SGLT2 inhibitors were found to lower the risk of CKD progression regardless of baseline eGFR or albuminuria, including in patients with stage 4 CKD or minimal albuminuria, supporting their routine use to improve kidney outcomes across the full spectrum of kidney function among patients with type 2 diabetes, CKD, or heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
- Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
- Department of Public Health and Primary Care, British Heart Foundation Cardiovascular Epidemiology Unit and Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, United Kingdom.
- Department of Cardiology (CVK) of German Heart Center Charité, Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedi…
- Mount Sinai Heart, New York, New York.
- Baylor Scott and White Research Institute, Temple, Texas.
Zitieren
APA
Neuen, B. L., Fletcher, R. A., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Docherty, K. F., Inzucchi, S. E., Jardine, M. J., Mahaffey, K. W., McCausland, F. R., McGuire, D. K., McMurray, J. J. V., Neal, B., Packer, M., Patel, S. M., Perkovic, V., Sabatine, M. S., Sardell, R. J., …, & SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (SMART-C) (2026). SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria. JAMA, 335(3), 233. https://doi.org/10.1001/jama.2025.20834
Vancouver
Neuen BL, Fletcher RA, Anker SD, Bhatt DL, Butler J, Cherney DZI, et al. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria. JAMA. 2026;335(3):233. doi:10.1001/jama.2025.20834
BibTeX
@article{Neuen2026,
author = {Neuen, Brendon L and Fletcher, Robert A and Anker, Stefan D and Bhatt, Deepak L and Butler, Javed and Cherney, David Z I and Docherty, Kieran F and Inzucchi, Silvio E and Jardine, Meg J and Mahaffey, Kenneth W and McCausland, Finnian R and McGuire, Darren K and McMurray, John J V and Neal, Bruce and Packer, Milton and Patel, Siddharth M and Perkovic, Vlado and Sabatine, Marc S and Sardell, Rebecca J and Solomon, Scott D and Vaduganathan, Muthiah and Wanner, Christoph and Wheeler, David C and Zannad, Faiez and Haynes, Richard and Staplin, Natalie and Herrington, William G and Heerspink, Hiddo J L and SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (SMART-C), SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (SMART-C)},
title = {SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria},
journal = {JAMA},
year = {2026},
volume = {335},
number = {3},
pages = {233},
doi = {10.1001/jama.2025.20834}
}
EUVIMED